Context Therapeutics (NASDAQ:CNTX) Stock Rating Lowered by Zacks Research

Context Therapeutics (NASDAQ:CNTX) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Monday, Zacks reports.

A number of other analysts have also recently issued reports on the company. Weiss Ratings cut Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Wall Street Zen cut Context Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 20th. Maxim Group decreased their price target on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th. Lifesci Capital downgraded shares of Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Finally, Citigroup reissued an “outperform” rating on shares of Context Therapeutics in a report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $6.17.

Context Therapeutics Stock Down 9.8%

CNTX stock opened at $0.28 on Monday. Context Therapeutics has a twelve month low of $0.27 and a twelve month high of $3.62. The company has a market cap of $25.27 million, a PE ratio of -0.57 and a beta of 1.71. The business’s 50-day simple moving average is $0.40 and its 200 day simple moving average is $1.22.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.06). On average, equities research analysts anticipate that Context Therapeutics will post -0.45 EPS for the current year.

Institutional Investors Weigh In On Context Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CNTX. Sanctuary Advisors LLC bought a new stake in Context Therapeutics in the first quarter valued at $51,000. Two Sigma Securities LLC raised its stake in Context Therapeutics by 388.7% during the second quarter. Two Sigma Securities LLC now owns 61,444 shares of the company’s stock worth $34,000 after acquiring an additional 48,871 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Context Therapeutics during the second quarter valued at $29,000. Bank of America Corp DE bought a new position in shares of Context Therapeutics during the second quarter valued at $30,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Context Therapeutics during the first quarter valued at $211,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing targeted treatments for solid tumors, with an emphasis on therapies designed to address cancers with limited treatment options. The company is headquartered in Philadelphia, Pennsylvania, and its activities are centered on the discovery and clinical development of oncology medicines.

Context’s lead program is CTIM-76, an investigational bispecific T-cell engager designed to bind Claudin 6 (CLDN6) on tumor cells and CD3 on T cells.